Changes in Regional Cerebral Blood Flow With Venlafaxine in the Treatment of Major Depression

OBJECTIVE: Neuroimaging studies reveal abnormalities of regional cerebral blood flow (rCBF) in major depression. In this study the authors prospectively investigated rCBF and clinical response to venlafaxine, a novel antidepressant. METHOD: A trial of venlafaxine was performed with seven patients re...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of psychiatry 2003-02, Vol.160 (2), p.374-376
Main Authors: Davies, Julia, Lloyd, Keith R., Jones, Ivor K., Barnes, Anna, Pilowsky, Lyn S.
Format: Article
Language:English
Subjects:
Adult
Antidepressive Agents, Second-Generation - pharmacology
Antidepressive Agents, Second-Generation - therapeutic use
Biological and medical sciences
Brain
Brain - blood supply
Brain - diagnostic imaging
Brain - drug effects
Cerebral Cortex - blood supply
Cerebral Cortex - diagnostic imaging
Clinical trials
Cyclohexanols - pharmacology
Cyclohexanols - therapeutic use
Depressive Disorder - diagnostic imaging
Depressive Disorder - drug therapy
Depressive Disorder - physiopathology
Drug therapy
Female
Humans
Limbic System - blood supply
Limbic System - diagnostic imaging
Male
Medical sciences
Mental depression
Middle Aged
Neuropharmacology
Pharmacology. Drug treatments
Psychiatric Status Rating Scales
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Regional Blood Flow - drug effects
Technetium Tc 99m Exametazime
Tomography, Emission-Computed, Single-Photon
Treatment Outcome
Venlafaxine Hydrochloride
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE: Neuroimaging studies reveal abnormalities of regional cerebral blood flow (rCBF) in major depression. In this study the authors prospectively investigated rCBF and clinical response to venlafaxine, a novel antidepressant. METHOD: A trial of venlafaxine was performed with seven patients referred with ICD-10 major depression. At entry and 6-week follow-up, the Beck Depression Inventory and Hamilton Depression Rating Scale were administered and rCBF was measured by means of single photon emission computed tomography with [99mTc]hexamethylpropyleneamine oxime. Blood flow changes were explored with statistical parametric mapping. RESULTS: The subjects showed significant improvement after treatment. Statistical parametric mapping analysis revealed increased rCBF bilaterally in the thalamus and decreased rCBF in the left occipital lobe, right cerebellum, and temporal cortex bilaterally. CONCLUSIONS: These data confirm limbic cortical rCBF changes associated with effective antidepressant treatment.
ISSN:0002-953X
1535-7228
DOI:10.1176/appi.ajp.160.2.374